Creatine Monohydrate In ALS: Effects On Strength, Fatigue, Respiratory Status And ALSFRS
| Effect | None |
| Trial Design | Double blind |
| Trial Length | 6+ Months |
| Number of Subjects | 107 |
| Sex | Both Genders |
| Age Range | 45-64, 65+ |
5 g/day for 9 months (following 10 g/day for five days) failed to benefit well-being, functional capacity, lung function, or muscular capacity as assessed by Maximal Voluntary Isometric Contraction (MVIC). The treatment proved safe, however, and the risk of death was nonsignificantly reduced.
